论文部分内容阅读
目的:评估采用多学科单中心CCCG-HB-2016方案治疗儿童肝母细胞瘤（HB）的临床疗效，分析此方案在临床上的可行性及安全性。方法:前瞻性研究本院2016年8月~2020年3月确诊的36例HB患儿多学科CCCG-HB-2016方案治疗的临床疗效。结果:36例患儿中男20例，女16例。患儿AFP均增高，范围为2 792～2 253 000 ng/ml，AFP与肿瘤危险度分层之间差异有统计学意义（n H=14.973，n P<0.05）。病理分型包括上皮型、上皮-间叶混合型，以上皮型多见，分别为28例（77.78%）、8例（22.22%）。肿瘤危险度分层与手术切除肝叶之间差异有统计学意义（n H=8.847，n P<0.05）。化疗不良反应主要为骨髓抑制，低、中、高危组骨髓抑制发生率分别为58.33%（35/60）、73.49%（61/83）、80.23%（69/86）。随访至2020年3月底，中位随访时间21.9个月，中位生存期为22.5个月，总生存率（OS）为97.2%，无事件生存率（EFS）为83.3%。n 结论:多学科CCCG-HB-2016方案治疗后手术成功率高，术后化疗不良反应以骨髓抑制多见，有较好的可行性、安全性。“,”Objective:To evaluate the clinical efficacy of multi-disciplinary single center's CCCG-HB-2016 regimen in the treatment of hepatoblastoma (HB) in children.Methods:Clinical data of 36 HB patients treated with CCCG-HB-2016 program from Aug 2016 to March 2020 were analyzed.Results:These 36 patients included 20 boys and 16 girls. The serum AFP was all higher than 2 792 ng/ml,there was a correlation between AFP and tumor risk stratification (n H=14.973, n P<0.05). Twenty eight cases (77.78%) were epithelial type and 8 cases (22.22%) were mixed epithelial mesenchymal type.All children were treated by tumor resection combined with chemotherapy, and there was a correlation between tumor risk stratification and surgical resection of liver lobe (n H=8.847, n P<0.05). The probability of bone marrow suppression in the low-risk group was 58.33% (35/60),that in the intermediate-risk group was 73.49% (61/83) and in the high-risk group was 80.23% (69/86).All 36 cases were followed up to March 31, 2020,with an average follow-up of 21.9 months and the median survival was 22.5 months.The overall survival rate (OS) and event-free survival rate (EFS) were 97.2% and 83.3% respectively.n Conclusions:The multidisciplinary CCCG-HB-2016 regimen was with a high success rate and along with a high incidence of bone marrow suppression.